

Brodalumab

Cat. No.:	HY-P9925
CAS No.:	1174395-19-7
Target:	Interleukin Related
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Brodalumab (AMG 827) is a human anti-interleukin-17-receptor IgG2 monoclonal antibody that can be used for the research of moderate-to-severe plaque psoriasis and rheumatoid arthritis ^{[1][2]} .
IC ₅₀ & Target	IL-17R ^[1]
In Vitro	Brodalumab (AMG 827) blocks the biological activity of IL-17A, IL-17F and IL17-A/F heterodimer signaling through the IL-17RA/RC complex, as well as IL-25 (IL-17E) signaling through the IL-17RA/RB complex ^[2] . Brodalumab is capable of inhibiting the inflammatory process in psoriasis ^[2] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- SSRN. 2023 Aug 2.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Papp KA, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med. 2012 Mar 29;366(13):1181-9.

[2]. Martin DA, et al. A phase Ib multiple ascending dose study evaluating safety, pharmacokinetics, and early clinical response of brodalumab, a human anti-IL-17R antibody, in methotrexate-resistant rheumatoid arthritis. Arthritis Res Ther. 2013 Oct 25;15(5):R164.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA